S&P Global Ratings credit analyst Kim Logan drops in on the show to answer some questions on the ratings of generic drug giant, Mylan NV. Kim shares her views on the ratings on Mylan, its product pipeline, the EpiPen controversy, and S&P’s expectations for de-levering at the company.

S&amp;P Global Ratings credit analyst Kim Logan drops in on the show to answer some questions on the ratings of generic drug giant, Mylan NV. Kim shares her views on the ratings on Mylan, its product pipeline, the EpiPen controversy, and S&amp;P’s expectations for de-levering at the company.

The S&P Pharma Dose – Episode 18: Focus on Mylan NV

S&P Global Ratings Podcast. Tune in for S&P Global Ratings analysts' opinions on trends and events that affect the global markets and your investment decisions. Download the S&P Global Ratings' Podcast to any portable audio device or your desktop. Make the most of your time and stay on top of important business developments around the world. Listen in! Our CreditMatters videos and podcasts provide an easy and informative way to keep up with S&P Global Ratings' global perspective on important credit market developments anytime, anywhere.

Business

S&amp;P Global Ratings Podcast. Tune in for S&amp;P Global Ratings analysts' opinions on trends and events that affect the global markets and your investment decisions. Download the S&amp;P Global Ratings' Podcast to any portable audio device or your desktop. Make the most of your time and stay on top of important business developments around the world. Listen in! Our CreditMatters videos and podcasts provide an easy and informative way to keep up with S&amp;P Global Ratings' global perspective on important credit market developments anytime, anywhere.

Share The S&P Pharma Dose – Episode 18: Focus on Mylan NV

Sign up to save your podcasts

The S&P Pharma Dose – Episode 18: Focus on Mylan NV

The S&P Pharma Dose – Episode 18: Focus on Mylan NV